Lifeward Stock Price, News & Analysis

Lifeward Ltd. (Nasdaq: LFWD) is a healthcare company in the medical devices sector that designs, develops, and commercializes technologies for physical rehabilitation and recovery. According to company disclosures, Lifeward focuses on life-changing solutions that deliver functional and health benefits in clinical settings, as well as in the home and community, for individuals with physical limitations or disabilities. The company was founded in 2001 and has operations in the United States, Israel, and Germany.

Lifeward’s portfolio centers on advanced medical technology that supports mobility, rehabilitation, and neuromuscular conditioning. Across multiple company press releases and SEC filings, Lifeward describes a product family that includes the ReWalk Exoskeleton, the ReWalk 7 Personal Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES System (also referred to as MyoCycle FES bikes), and the AlterG Anti-Gravity System. These technologies are positioned by the company as part of a continuum of care, from intensive clinical rehabilitation to ongoing use in home and community environments.

Business focus and product portfolio

Company materials describe Lifeward as a global medical technology business that aims to transform the lives of people with spinal cord injury and other physical limitations. Its ReWalk Personal Exoskeleton and ReWalk 7 Personal Exoskeleton are highlighted in multiple news releases as personal robotic exoskeleton systems for individuals with spinal cord injury, including Medicare and Medicare Advantage beneficiaries. Lifeward reports that it has obtained a formal reimbursement pathway from the U.S. Centers for Medicare & Medicaid Services (CMS) for personal exoskeletons and has been working with Medicare and Medicare Advantage plans on prior authorization and payment for ReWalk 7 systems.

The AlterG Anti-Gravity System is cited by the company as another core product line, with Lifeward emphasizing its intent to achieve sustainable profitability from FDA-approved MedTech products such as the ReWalk and AlterG product lines. The ReStore Exo-Suit and MyoCycle FES System are also repeatedly listed as part of the Lifeward portfolio, supporting physical rehabilitation and recovery across different care settings.

Geographic footprint and markets

Lifeward states that it operates in the United States, Israel, and Germany, with Germany described as a key market for exoskeleton sales. In company communications, Lifeward notes that previous generations of the ReWalk Exoskeleton have been available in Europe since an initial CE mark in 2010, and that the European market is served through its Lifeward GmbH salesforce in Germany. The company reports that reimbursement for personal exoskeletons has been broadly established for individuals in Germany, supported by supply contracts with major insurance carriers.

The company has also disclosed an expansion of international distribution for the ReWalk Personal Exoskeleton through a partner-led model. Under a distribution agreement with Verita Neuro, Lifeward reports that ReWalk will be offered in Mexico, Thailand, and the United Arab Emirates, with Verita Neuro integrating ReWalk into its treatment modalities for people living with neurological and spinal cord injuries.

Regulatory and reimbursement milestones

Lifeward highlights several regulatory and reimbursement developments that are central to its business model. The company announced that it received CE mark approval for the ReWalk 7 Personal Exoskeleton, clearing this seventh-generation system for commercial sale in Europe. In its disclosures, Lifeward notes that European customers, particularly in Germany, represent a significant portion of exoskeleton sales and that reimbursement processes have been established for individuals with statutory health insurance coverage.

In the United States, Lifeward reports that CMS implemented a formal Medicare reimbursement pathway for personal exoskeletons. Subsequent press releases describe the company’s progress in securing prior authorization approvals from Medicare Advantage plans, including UnitedHealthcare and a Humana Medicare Advantage Plan, for ReWalk 7 Personal Exoskeleton systems. Lifeward states that these approvals are expected to support more predictable reimbursement, improved cash flow dynamics, and a clearer foundation for scalable growth in the U.S. market.

Strategic evolution toward a biomedical portfolio

In a strategic transaction announced with Oramed Pharmaceuticals Inc., Lifeward describes a plan to evolve into a disciplined biomedical portfolio company that combines medical technology and biotechnology assets. Under definitive agreements, Oramed will transfer its Protein Oral Delivery (POD™) technology to Lifeward, while obtaining a significant ownership interest in the company. Lifeward explains that POD™ is a protein oral delivery platform designed to enable oral administration of drugs that are typically injectable, and that the technology has been applied in clinical programs such as ORMD-0801, an oral insulin candidate.

According to the companies’ joint announcements, the transaction structure is intended to provide Lifeward with access to capital, while Oramed will manage and fund the anticipated POD™ clinical program. Lifeward states that, upon consummation of the transaction and subject to shareholder approval and other closing conditions, it plans to focus on three main objectives: achieving sustainable profitability from existing MedTech products such as the ReWalk and AlterG product lines; deploying capital selectively toward assets with defined milestones and risk-adjusted returns; and building a balanced biomedical portfolio that combines near-term revenue with longer-term biotech innovation.

Capital markets and corporate status

Lifeward’s ordinary shares trade on the Nasdaq Capital Market under the symbol LFWD. The company is incorporated in the State of Israel and identifies itself as a smaller reporting company in SEC registration statements. In 2025, Lifeward filed a registration statement on Form S-1 and an amendment to that registration statement relating to offerings of ordinary shares and warrants, and it entered into a securities purchase agreement for a best-efforts public offering of ordinary shares and warrants.

In an 8-K filing dated August 5, 2025, Lifeward reported receiving a Nasdaq notice of deficiency regarding the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company disclosed that this notice did not immediately affect the listing or trading of its ordinary shares and that it was granted a 180-day period, with the possibility of an additional compliance period, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a required period. The filing states that the company intends to monitor the closing bid price and consider options to regain compliance, though there can be no assurance of success.

In November 2025, Lifeward also reported entering into a Secured Promissory Note with Oramed Ltd. for a $3.0 million loan secured by a lien on the company’s cash, with interest and conversion terms described in the 8-K. The note includes customary covenants and events of default and is convertible into Lifeward ordinary shares at a specified conversion price, subject to a beneficial ownership limitation.

Corporate governance and leadership context

Company proxy materials and press releases describe ongoing corporate governance activities, including annual shareholder meetings, director elections, and executive compensation approvals. Lifeward’s definitive proxy statement for its 2025 annual meeting outlines proposals such as the re-election of Class II directors, approval of a 2025 Incentive Compensation Plan, amendments to increase authorized share capital, and an advisory vote on executive compensation.

In an 8-K filing, Lifeward reported the appointment of a new Chief Financial Officer, along with details of his employment terms, equity awards, and severance protections. A separate press release announced the appointment of Bob Marshall as Chairman of the Board, highlighting his financial leadership and healthcare public company experience. Company communications also note that Lifeward was formerly known as ReWalk Robotics and that it operates under the leadership of a President and Chief Executive Officer with extensive experience in the diabetes and medical technology sectors.

Position within the medical devices and healthcare sector

Across its public communications, Lifeward consistently characterizes itself as a global medical technology company focused on individuals with physical limitations or disabilities, particularly those with spinal cord injury. Its emphasis on personal exoskeletons, anti-gravity systems, exo-suits, and functional electrical stimulation systems places the company within the medical devices and rehabilitation technology segment of the healthcare sector.

The company’s disclosures also indicate an increasing emphasis on payer engagement and reimbursement frameworks, especially in the United States and Germany, as a key component of its commercial strategy. At the same time, the planned integration of Oramed’s POD™ technology introduces a biotechnology dimension to Lifeward’s business, with exposure to markets for oral delivery of protein and peptide-based therapies.

FAQs about Lifeward Ltd. (LFWD)

• What does Lifeward Ltd. do?
  Lifeward Ltd. designs, develops, and commercializes medical technologies that support physical rehabilitation and recovery for individuals with physical limitations or disabilities. The company highlights products such as the ReWalk Exoskeleton, ReWalk 7 Personal Exoskeleton, ReStore Exo-Suit, MyoCycle FES System, and AlterG Anti-Gravity System.
• When was Lifeward founded?
  Company press releases state that Lifeward was founded in 2001.
• Where does Lifeward operate?
  Lifeward reports that it has operations in the United States, Israel, and Germany, and that it serves the European market through its Lifeward GmbH salesforce in Germany. It has also disclosed distribution arrangements for the ReWalk Personal Exoskeleton in Mexico, Thailand, and the United Arab Emirates through Verita Neuro.
• On which exchange is LFWD stock listed?
  According to SEC filings, Lifeward’s ordinary shares, par value NIS 1.75 per share, are listed on the Nasdaq Capital Market under the trading symbol LFWD.
• What are Lifeward’s main products?
  Lifeward identifies several key product lines in its public statements: the ReWalk Exoskeleton and ReWalk 7 Personal Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES System (or MyoCycle FES bikes), and the AlterG Anti-Gravity System.
• How is Lifeward involved in biotechnology?
  In a strategic transaction with Oramed Pharmaceuticals, Lifeward agreed to acquire Oramed’s Protein Oral Delivery (POD™) technology. This platform is designed to enable oral delivery of therapies that are typically injectable, including an oral insulin candidate, and is expected to be managed and funded clinically by Oramed while Lifeward retains exposure to its potential upside.
• Has Lifeward received any Nasdaq compliance notices?
  In an 8-K dated August 5, 2025, Lifeward reported receiving a Nasdaq notice that its closing bid price had been below the $1.00 minimum required by Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days. The company stated that this was a notice of deficiency and not an immediate delisting, and that it was granted a 180-day period, with potential extension, to regain compliance.
• What reimbursement developments has Lifeward reported?
  Lifeward has disclosed that CMS finalized a Medicare reimbursement pathway for personal exoskeletons and that the company has been submitting claims on behalf of beneficiaries. It has announced prior authorization approvals and payments from Medicare Advantage plans, including UnitedHealthcare and a Humana Medicare Advantage Plan, for ReWalk 7 Personal Exoskeleton systems.
• Is Lifeward still an operating company?
  Based on recent press releases and SEC filings, Lifeward continues to report financial results, enter into financing arrangements, pursue regulatory approvals such as CE mark for ReWalk 7, and announce strategic transactions and board appointments. There is no indication in the provided materials that the company has ceased operations.
• What is Lifeward’s corporate structure and jurisdiction?
  SEC registration statements identify Lifeward Ltd. as a company incorporated in the State of Israel, with ordinary shares registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the Nasdaq Capital Market.